A team reported an mRNA engineering approach that enhances mesenchymal stem cells (MSCs) to create DC‑25, an allogeneic cell therapy candidate designed to improve immunotherapeutic potency. The platform aims to combine transient mRNA programming with off‑the‑shelf manufacturing to bypass limitations of autologous cell therapies. The study demonstrates improvements in immune modulation and antigen-presenting functions in engineered MSCs, positioning DC‑25 for applications where scalable allogeneic products can replace bespoke autologous manufacturing. Transient mRNA payloads reduce genomic-integration risk while enabling functional reprogramming. Translational steps will focus on in vivo efficacy, immunogenicity profiling and establishing GMP‑compatible mRNA manufacturing and cryopreservation processes prior to clinical trials.